Meyer Andrew Hollman 4
4 · Janux Therapeutics, Inc. · Filed May 2, 2025
Insider Transaction Report
Form 4
Meyer Andrew Hollman
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2025-05-01$4.21/sh+3,333$14,032→ 85,472 total - Sale
Common Stock
2025-05-01$31.95/sh−2,933$93,703→ 82,539 total - Sale
Common Stock
2025-05-01$32.60/sh−400$13,041→ 82,139 total - Exercise/Conversion
Stock Option (right to buy)
2025-05-01−3,333→ 87,332 totalExercise: $4.21Exp: 2031-03-09→ Common Stock (3,333 underlying)
Footnotes (4)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.
- [F2]The weighted average sale price for the transaction reported was $31.9479 and the range of prices were between $31.44 and $32.38. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The weighted average sale price for the transaction reported was $32.6034 and the range of prices were between $32.52 and $33.66. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F4]Immediately exercisable.